BTIG raised the firm’s price target on Intuitive Surgical to $459 from $451 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results in the MedTech sector. The group struggled to sustain its Q1 momentum in Q2 as the sector underperfored the S&P, though moving forward, investors that can embrace the volatility will be rewarded as the sector can outperform in an easing interest rate environment, the analyst tells investors in a research note. BTIG adds that it sees pockets of outperformance, notably in Robotics and Ophthalmology, which carry names that are consensus favorites and have been throughout most of the year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- Options Volatility and Implied Earnings Moves This Week, July 15 – July 19, 2024
- Citi ups Intuitive Surgical target, opens ‘negative catalyst watch’
- Intuitive Surgical price target raised to $490 from $435 at Piper Sandler
- ISRG, PFE, or DXCM: Which Healthcare Stock Could Generate the Highest Returns?
- Intuitive Surgical price target raised to $425 from $385 at Evercore ISI